MannKind (MNKD) Posts Quarterly Results
MannKind (NASDAQ:MNKD) issued its quarterly earnings data on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.07, StockRatingsNetwork reports.
In other MannKind news, VP David Thomson unloaded 30,000 shares of the stock on the open market in a transaction dated Thursday, August 7th. The shares were sold at an average price of $8.16, for a total transaction of $244,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of MannKind (NASDAQ:MNKD) opened at 8.13 on Monday. MannKind has a one year low of $3.80 and a one year high of $11.48. The stock’s 50-day moving average is $9.48 and its 200-day moving average is $7.40. The company’s market cap is $3.073 billion.
MNKD has been the subject of a number of recent research reports. Analysts at ISI Group downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday, July 1st. They now have a $11.00 price target on the stock, up previously from $10.00. On the ratings front, analysts at MLV & Co
downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday, July 1st. They now have a $11.00 price target on the stock, up previously from $10.00. They noted that the move was a valuation call. Finally, analysts at Brinson Patrick raised their price target on shares of MannKind from $12.00 to $15.00 in a research note on Monday, June 30th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $9.93.
MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.